IPSEN S.A. PORT. EO 1/ FR0010259150 /
| 2024-11-09 11:51:24 AM | Chg. 0.00 | Volume | Bid11:51:24 AM | Ask11:51:24 AM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 109.80EUR | 0.00% | - Turnover: - |
109.80Bid Size: - | 111.10Ask Size: - | 9.24 bill.EUR | 1.09% | 14.16 |
GlobeNewswire
07-26
Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and K...
GlobeNewswire
07-25
Ipsen delivers strong results in the first half of 2024, progresses on launches and upgrades its ful...
GlobeNewswire
07-25
Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for ...
GlobeNewswire
07-11
Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug con...
GlobeNewswire
07-02
Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroend...
GlobeNewswire
06-10
Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primar...
GlobeNewswire
06-07
Ipsen and Marengo Therapeutics announce second strategic partnership to advance precision T cell eng...
GlobeNewswire
06-05
Ipsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with...
GlobeNewswire
04-24
Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines...
GlobeNewswire
04-22
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological di...
GlobeNewswire
04-02
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid t...
GlobeNewswire
02-13
Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreat...
GlobeNewswire
2023-12-07
Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the trea...
GlobeNewswire
2023-12-07
Capital Markets Day 2023 - Ipsen outlines next phase of growth & transformation and provides new mid...
GlobeNewswire
2023-11-13
Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaki...
GlobeNewswire
2023-10-26
Ipsen delivers solid sales growth in the first nine months of 2023 and confirms its full-year guidan...
GlobeNewswire
2023-10-23
Ipsen updates on E.U. Marketing Authorisation Application for odevixibat in Alagille syndrome
GlobeNewswire
2023-09-04
Ipsen nominates Pascal Touchon to its Board of Directors as new independent director
GlobeNewswire
2023-09-01
Ipsen announces change in R&D leadership: Howard Mayer to retire, succeeded by Christelle Huguet
